You are here: Industry Insights > Bayer

News List

Curadev and Bayer agreement shows switch in gears towards STING antagonists: GlobalData expresspharma
April 17, 2020
Globally, there are 42 STING agonists and 8 STING antagonists under development.
Nubeqa authorised in Europe for certain prostate cancer patients pharmatimes
April 01, 2020
The European Commission has granted marketing authorisation in the European Union (EU) for Bayer’s Nubeqa (darolutamide).
Bayer enlists Curadev in STING antagonist collaboration pharmatimes
March 26, 2020
Bayer and Curadev have announced a novel research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program.
Bayer signs drug development and licensing deal with Curadev pharmaceutical-technology
March 25, 2020
German healthcare company Bayer has entered into a research collaboration and licence agreement with India-based drug discovery firm Curadev.
Bayer and Curadev sign research collaboration and license agreement to develop novel STING antagonists across indications expresspharma
March 24, 2020
The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.
Bayer Shuts Down Locations amid COVID-19 Concerns americanpharmaceuticalreview
March 13, 2020
Bayer will temporarily closing locations inNew Jersey locations and Missouri over concerns that an employee may have contracted COVID-19.
WuXi Biologics to acquire drug manufacturing plant in Germany pharmaceutical-technology
January 19, 2020
WuXi Biologics has signed an acquisition agreement to take over a Bayer’s drug product manufacturing plant in Leverkusen, Germany. The Leverkusen plant will be the Chinese firm’s first drug product facility in Europe bolstering its commercial manufacturin
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany(1) PharmaSources/Wuxi Biologics
January 16, 2020
WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer
Bayer to commercialise Daré’s monthly contraceptive Ovaprene in US pharmaceutical-business-review
January 15, 2020
Bayer has entered into a licence agreement with Daré Bioscience to commercialise investigational contraceptive product called Ovaprene in the US.
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery worldpharmanews
January 14, 2020
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page